#USA #New York #Securities Class Action #Levi Korsinsky #GeneDx Holdings

Legal Notice for GeneDx Holdings Corp. Investors

A recent announcement from Levi & Korsinsky, LLP has caught the attention of investors in GeneDx Holdings Corp. (NASDAQ: WGS) as a deadline approaches for a significant securities class action lawsuit. This case involves serious allegations against the company’s top executives, namely the CEO and CFO, who have been named as defendants in an ongoing legal battle that concerns investor losses tied to stock price declines and questionable corporate practices.

What's Happening?

The lawsuit, which encompasses those who purchased shares between April 16, 2025, and May 4, 2026, comes on the heels of GeneDx's concerning financial disclosures. The company reported a staggering 49.20% loss in share value, equivalent to $33.42 per share, following a shocking announcement of a $31.2 million impairment charge and a drastic reduction in its full-year revenue guidance by roughly $65 million. This financial plight has led to investors questioning the integrity and transparency of the company's management.

In particular, the complaint identifies Katherine Stueland, CEO, and Kevin Feeley, CFO, as having significant control over the company’s public disclosures. Allegations suggest these executives were fully aware of the ongoing issues regarding the viability of Fabric Genomics—an acquisition that was touted as a game-changer for revenue generation—yet continued to make positive public statements to investors.

Who Can Participate?

Investors who believe they have suffered losses due to these developments may qualify to join the lawsuit and seek recovery. The deadline for applying as the lead plaintiff is set for August 3, 2026, which is crucial for individuals wishing to take on a more active role in the proceedings. Even if you do not aim to be a lead plaintiff, you can participate in any recovery without further action before this deadline.

To ensure you stay informed and eligible, it is advised for potential participants to gather relevant brokerage records, including information on purchase dates, share quantities, and prices. Those who have sold their shares during this class period should not be dissuaded; eligibility for recovery is based on share purchases rather than holdings.

Understanding the Allegations

At the core of the complaint are the accusations that the two individual defendants, Stueland and Feeley, failed to uphold their fiduciary duties by allegedly allowing misleading statements about their operations to persist. The lawsuit points to their positions of authority and the Sarbanes-Oxley Act's requirements, which demand executives personally certify the accuracy of company financial disclosures. The contention is that during the time they certified these filings, they were aware—or reckless in disregarding—that substantial misrepresentations regarding the integration and value of Fabric Genomics were being made to investors.

The allegations hinge on several critical facts:

• - Both executives were involved in daily operations, granting them insight into the company's true performance compared to public statements.
• - They participated in earnings calls where misleading assertions were made concerning the acquisition of Fabric Genomics.
• - Their roles in setting revenue expectations, which drastically changed, directly impacted investor confidence.

What Should You Do Now?

Investors are urged to reach out to Levi & Korsinsky for a no-obligation evaluation to discuss their potential claims. Notably, there are no upfront costs to join, as these securities class actions operate on a contingency basis. Hence, investors can opt-in without financial commitment.

In a world where corporate transparency is paramount, the responsibility placed on executives to navigate these legal waters is more critical than ever. As stated by Joseph E. Levi, Esq., corporate officers hold a duty to furnish accurate and complete public statements. For GeneDx Holdings investors, the ongoing litigation serves as a pivotal moment forcing accountability amidst rising concerns over deceptive practices.

Don't miss out on the opportunity to take part in this recovery process. To join the conversation or gather more details about your eligibility or the status of this case, contact Levi & Korsinsky at (212) 363-7500 or via email at [email protected]. Stay informed; your financial future may depend on it.